Children newly diagnosed with CeD took the probiotic for 12 weeks, but no significant differences between the treatment and placebo groups in terms of anti-TG2 IgA Abs, fecal calprotectin or hemoglobin were found. This evidence concerns the gene TGM2 and cranioectodermal dysplasia.